Introduction
The International Society for the Study of Vulvovaginal Disease (ISSVD) defines vulvodynia as chronic vulvar pain without visible dermatosis [44] . An estimated 10% to 15% of women will meet the diagnostic criteria at some time in their lives [31] . Two major vulvodynia categories have been defined by the ISSVD: ''localized'' and ''generalized'' subtypes. Displayed in Fig. 1A , localized provoked vulvodynia (LPV) presents with a characteristic pattern of mechanical allodynia localized to the vulvar vestibule, whereas generalized vulvodynia (GVD) shows a more diffuse pain pattern involving part or all of the pudendal nerve distribution and beyond. A number of researchers suspect that LPV and GVD may represent a continuum of the same condition rather than 2 distinct clinical entities. Clinically 2 subgroups of patients with LPV have been described: those with primary LPV, defined as dyspareunia from the first attempt of sexual intercourse; and those with secondary LPV, in which dyspareunia appears after a period of pain-free sexual intercourse.
Vulvodynia often occurs in the context of other comorbid pain conditions [1, 11, 50] , with irritable bowel syndrome and fibromyalgia being the most prevalent. These clinical observations and epidemiological studies highlight the heterogeneity of vulvar pain syndromes, suggesting different peripheral and central neurophysiological mechanisms relevant to the grouping with different comorbid pain conditions. As our understanding of vulvodynia evolves beyond the rudimentary classification of LPV, GVD, and primary and secondary types, nomenclature will be based on a clearer understanding of disease phenotype with improved diagnostic reliability and better-defined disease models.
This review will focus on progress in vulvodynia basic research. Because LPV is the more common subtype and has had a greater research emphasis, this review will reflect that focus. In addition to allodynia to light touch of the vulvar vestibule, a number of psychophysiologic events have been recognized to occur concurrently and to varying degrees in afflicted individuals, these include:
Pro-inflammatory cell migration to the vulvar vestibule [10, 12, 13, 37] . Local production and release of pro-inflammatory, paininducing substances [9, 20] . Regional hyperinnervation of C fibers [8, 58, 59, 64] . Regional lowering thresholds to varied stimuli [7, 48, 53, 66] . Development of central sensitization [19, 28, 32, 47, 65] . Autonomic dysfunction, ie, postural hypotension [19, 32] . Manifestation of somatization, depression, anxiety, and hypervigilance [41, 47, 54] . Superimposed pelvic floor muscle hypercontractility resulting in introital narrowing and muscle pain [23, 24, 29, 30] . Sexual dysfunction [3, 42, 54, 60] .
Genetics of vulvodynia
Several studies suggest a genetic predisposition to the development of LPV, potentially based on 3 mechanisms: an influence on the risks of recurrent vulvovaginal candidiasis (RVVC), an altered inflammatory response, an increased sensitivity to pain.
Vulvovaginal infections are frequently identified as the inciting event for the development of LPV. It has been postulated that an inability to clear these infections and the subsequent inflammation produced may lead to the development of this condition. Both mannose-binding lectin (MBL) and NALP3 inflammosome are associated with defense against Candida species, and the genes that code for each are polymorphic. Women with RVVC have a higher MBL variant allele frequency than do controls 
